Cm. Lai et al., Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization, HUM GENE TH, 12(10), 2001, pp. 1299-1310
Pathological angiogenesis, or the production of new capillary vessels from
preexisting vasculature, within the eye is a serious event that often leads
to blindness. Upregulation of vascular endothelial growth factor (VEGF) ha
s been linked to neovascularization in the eye, suggesting that it could be
a suitable target to inhibit angiogenic changes. This work investigated wh
ether the presence of a proven antiangiogenic factor, the soluble variant o
f the VEGF receptor, sFlt-1, in the anterior chamber is sufficient to inhib
it new vessel formation in the cornea in an animal model of corneal neovasc
ularization. A recombinant adenovirus vector that can mediate efficient in
vivo gene transfer and expression in ocular cells was selected as a deliver
y agent. We have shown that after the injection of Ad.beta gal into the ant
erior chamber of normal and cauterized rat eyes, corneal endothelial cells
and cells of the trabecular meshwork were efficiently transduced and that b
eta -galactosidase (beta -Gal) expression was maintained up to 10 days post
injection. Cauterization significantly increased the amount of immunoreacti
ve VEGF in vehicle- or Ad.null-injected animals (t test, p< 0.001 and p< 0.
001, respectively). However, when cauterization was combined with Ad.sflt i
njection there was no statistically significant increase in the amount of i
mmunoreactive VEGF (p = 0.12). The injection of Ad.sflt into the anterior c
hamber slowed or inhibited VEGF-induced angiogenic changes. After cauteriza
tion, 100% of uninjected and vehicle- injected and 82% of Ad.null-injected
animals developed moderate to severe corneal angiogenesis in contrast to 18
% of Ad.sflt-injected animals. These in vivo results suggest that the trans
ient presence of antiangiogenic agents in the anterior chamber can be succe
ssfully used to inhibit the development of corneal angiogenesis.